As outlined in a meta-analysis including 77 VEGF inhibitors, severe hypertension occurred in 7.4%, cardiac dysfunction in 2.3%, arterial thromboembolism in 1.8%, and cardiac ischemic in 1.7% of patients, and there was no significant difference in cardiovascular risk between anti-VEGF monoclonal antibody and TKIs (98). The gene discussed is VEGFA; the disease is hypertensive disorder.